Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophil cell line
- PMID: 1352308
- DOI: 10.1210/jcem.75.1.1352308
Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophil cell line
Abstract
Pituitary tumors producing GH and PRL are morphologically classified as monomorphous bihormonal acidophil stem cell adenomas (ASCAs) which cause hyperprolactinemia and two tumor types which are usually associated with acromegaly, the monomorphous plurihormonal mammosomatotroph adenomas (MSAs) and bimorphous mixed somatotroph-lactotroph adenomas. We studied 12 MSAs, 2 ASCAs, and 10 mixed adenomas in vitro to assess the secretory behavior of these tumors diagnosed by immunohistochemistry and electron microscopy. GH release by MSAs and all but one mixed tumor was greater than that of PRL; the opposite was true of the ASCAs. One mixed tumor which caused impotence and hyperprolactinemia contained predominantly lactotrophs and released greater amounts of PRL than of GH in vitro. All 12 MSAs and 6 of 10 mixed tumors released alpha-subunit of glycoprotein hormones. Incubation with GHRH increased release of GH and PRL by all tumors and of alpha-subunit when present; the responses of all hormones were parallel among MSAs whereas among mixed adenomas, GH and alpha-subunit had greater responses than PRL. TRH stimulated GH, PRL, and alpha-subunit release by MSAs in parallel; among mixed adenomas, PRL response was generally greater than that of GH or alpha-subunit. SRIH markedly reduced GH release by all MSAs; it inhibited GH and alpha-subunit release by mixed tumors more than it affected PRL. Bromocriptine inhibited GH, PRL, and alpha-subunit release by most MSAs and mixed tumors but did not inhibit GH or PRL release by ASCAs. This study demonstrates release of GH, PRL, and alpha-subunit by these morphologically classified plurihormonal tumors in vitro. Variable quantities of GH and PRL released by the different tumor types correlate with immunohistochemical and clinical data. The dynamic studies indicate that regulation of GH, PRL, and alpha-subunit release can be affected by GHRH, TRH, SRIH, and bromocriptine in these adenomas and suggest differences in receptor status. Our data strengthen the view that these three plurihormonal adenomas of the acidophil cell line are not only morphologically but also functionally different and warrant separation.
Similar articles
-
Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture.J Clin Endocrinol Metab. 1985 May;60(5):985-93. doi: 10.1210/jcem-60-5-985. J Clin Endocrinol Metab. 1985. PMID: 2858494
-
Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.J Clin Endocrinol Metab. 1985 Jun;60(6):1148-53. doi: 10.1210/jcem-60-6-1148. J Clin Endocrinol Metab. 1985. PMID: 3923021
-
Human pituitary null cell adenomas and oncocytomas in vitro: effects of adenohypophysiotropic hormones and gonadal steroids on hormone secretion and tumor cell morphology.J Clin Endocrinol Metab. 1992 May;74(5):1128-34. doi: 10.1210/jcem.74.5.1569159. J Clin Endocrinol Metab. 1992. PMID: 1569159
-
Current pathological classification of pituitary adenomas.Acta Neurochir Suppl. 1996;65:1-3. doi: 10.1007/978-3-7091-9450-8_1. Acta Neurochir Suppl. 1996. PMID: 8738481 Review.
-
Pathophysiology of acromegaly.Endocr Rev. 1983 Summer;4(3):271-90. doi: 10.1210/edrv-4-3-271. Endocr Rev. 1983. PMID: 6354702 Review.
Cited by
-
Medical management of pituitary adenomas: structural and ultrastructural changes.Pituitary. 2002;5(2):133-9. doi: 10.1023/a:1022320732718. Pituitary. 2002. PMID: 12675510 Review.
-
The Clinicopathological Spectrum of Acromegaly.J Clin Med. 2019 Nov 13;8(11):1962. doi: 10.3390/jcm8111962. J Clin Med. 2019. PMID: 31766255 Free PMC article. Review.
-
A case of fugitive acromegaly, initially presented as invasive prolactinoma.Endocrine. 2010 Aug;38(1):1-5. doi: 10.1007/s12020-010-9341-5. Epub 2010 Apr 24. Endocrine. 2010. PMID: 20960094
-
Best Practice No 172: pituitary gland pathology.J Clin Pathol. 2003 Aug;56(8):561-8. doi: 10.1136/jcp.56.8.561. J Clin Pathol. 2003. PMID: 12890801 Free PMC article. Review.
-
A prospective multicenter octreotide dose response study in the treatment of acromegaly.J Endocrinol Invest. 1995 May;18(5):364-9. doi: 10.1007/BF03347839. J Endocrinol Invest. 1995. PMID: 7594225 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical